Purplevine IP

Xiaoyan Zhou of Purplevine IP explains how to protect IP in the rapidly developing area of AI medical devices in China, and the risks involved

Join Ude Lu, the chief IP counsel (US) of Purplevine IP, Helen Zhang, the litigation manager of Purplevine IP in Beijing, and Penny Sun, the brand protection manager of ABRO Industry, as they discuss evidence collection for patent enforcement in China and the US virtually with Managing IP on November 9 at 10am (US ET) / 3pm (UK) / 11pm (China)

Xiaoyan Zhou of Purplevine IP analyses the Fifth Set of Listing Standards for Medical Device Companies on STAR Market of the Shanghai Stock Exchange, which encourages companies to develop core technologies

Xiaoyan Zhou of Purplevine IP explains how the introduction of administrative measures for registering, and filing records relating to, medical devices in China should affect companies’ IP strategy

Xiaojuan Yu of Purplevine IP Group discusses the medical device industry in China and considers why changes to the law are welcomed

Ming Wen and Helen Zhang of Purplevine IP explains how the evolving patents law in China will give right holders a better chance to enforce their patent rights